Alzheimer; News from the web:
Roche, Lilly and the Alzheimer association all chip in to make a big study possible into the effectiveness of three Alzheimer drugs. All three drugs impact Alzheimer in a different way but all of them will help the science forward. The study is led by the Washington University at St Louis.
Read all about it HERE
visit us at AlzheimerHeadlines.com
Alzheimer; News from the web:
Until now we have always found that the presence in the brain of hyper active astrocytes probably increases the rate of the development of the feared amyloid plaques. A new study however has found that, in mice, reducing the hyper activity of the astrocytes actually increases the amyloid plaques. So now the plan is to see if we can manage the efficient working of the astrocytes to give them a hand in keeping the amyloid plaques under control.
Read all about it HERE
visit us at AlzheimerHeadlines.com
Alzheimer; News from the web:
Today’s link is a more in depth explanation of the discovery of the working of nuclear receptors. Certain nuclear receptors are essential for long-term memory formation, and pharmaceutical approaches that boost the function of these proteins — and the molecular machinery they set in motion — could one day restore memory function in those who have lost it.
Read all about it HERE
visit us at AlzheimerHeadlines.com
Alzheimer; News from the web:
Well the article in the Huffington post this morning certainly burst the bubble of many people who had relied on this herb.
A trail in France, an article in the Lancet for Neurology and an opinion from the Alzheimer association killed the hype and the consensus is that anyone who buys this over the counter herb in the expectation that it will do anything to slow down or prevent the disease, is wasting their money.
Read all about it HERE
visit us at AlzheimerHeadlines.com
Alzheimer; News from the web:
Over at nature they have provided a great overview over the current state of affairs concerning Alzheimer drugs and research.
They also highlight the enormous costs involved in doing the clinical trails and some of the devastating results we saw this summer.
It is difficult to keep investors interested and motivated but lately there are some new paths that may just be worth exploring. Great article
Read all about it HERE
visit us at AlzheimerHeadlines.com
Alzheimer; News from the web:
Researchers from Cleveland Clinic’s Lerner Research Institute and Anesthesiology Institute found that the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer’s disease.
Treatment with the compound restored cognition, memory and synaptic plasticity – a key neurological foundation of learning and memory – in an animal model.
“Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer’s disease,” Mohamed Naguib, lead researcher said in a statement.
Read all about it HERE
visit us at AlzheimerHeadlines.com